REQUEST A DEMO

Product launches: making the most of your one shot

Posted by Andre Moa on May 19, 2021 1:12:40 PM

While some errors are unforeseen, many can be prevented with better planning, coordination, communication and transparency in launch planning and implementation. In our article for PME, we make the case for why pharma companies need a launch execution platform that makes launch excellence the norm, builds the corporate launch memory, and streamlines efforts to save time for everyone involved in product launches.

 

The importance of a pharma product’s launch to its success cannot be overstated. A recent analysis by Deloitte showed that most new drugs continue with the revenue trajectory set at launch – around 70 percent of products that miss expectations at launch continue doing so in subsequent years, and around 80 percent of products that meet or beat expectations continue to do so afterward.

 

Read More

Topics: launch excellence, launch execution, product launches

Rethinking Launch Readiness in 2021: The New Normal in the Shadow of COVID

Posted by Andre Moa on Feb 24, 2021 3:50:37 PM

 

It is probably reasonable enough by now to talk about the launch readiness landscape for medicines and vaccines as pre- and post-COVID. We can also say with some certainty that nothing will ever be the same again.

Read More

Topics: launch readiness, launch strategy, launch effectiveness, launch readiness framework, launch plan, pharma tenders

5 Pharma Trends for 2021: Disruption and Transformation in the COVID Era

Posted by Andre Moa on Dec 3, 2020 5:43:38 PM

The COVID-19 pandemic has eclipsed every other development in healthcare and pharmaceuticals during 2020. It will likely do so next year as well. Looking ahead to 5 pharma trends for 2021 that will set the agenda for industry, it is hard to escape COVID-19 both as a challenge and a spur to new directions.

 

Read More

Topics: Pharma trends, launch trends, launch readiness, AI

2020 New Drug Approvals: Review of New FDA and EMA Marketing Authorisations

Posted by Andre Moa on Nov 17, 2020 11:21:59 AM

 

Any fears that COVID-19 might stem the flow of new drug approvals in 2020, depleting or diverting resources at regulatory agencies and their pharmaceutical clients, appear largely premature.

Read More

Topics: Pharma launch planning, launch readiness, EMA Approvals, FDA Approvals

How the coronavirus crisis could affect your new drug launch

Posted by Andre Moa on Apr 7, 2020 2:44:49 PM

 

The widespread disruption caused by the coronavirus pandemic is forcing pharmaceutical companies to think more creatively and flexibly about how their business model can accommodate new restraints such as home working, restricted face-to-face contact, travel bans, supply-chain bottlenecks, stalled clinical-trial recruitment, diverted healthcare budgets, closer scrutiny of drug reimbursement, and depleted staffing at regulatory agencies. Digital technology will be a crucial tool in addressing these challenges and softening the pandemic’s multiple potential impacts on drug launches.

Read More

Topics: Pharma launch planning, Pharma trends, Market access, launch readiness, Tender Management, #covid-19, coronavirus